Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...
Novo Nordisk (NVO) is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical companies next week. CEO Lars Jørgensen told reporters Thursday ...
Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...
Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly ...
Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.
Novo Nordisk 's ( NVO 3.84%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance ...
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results